Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056312 | 1.00 | FDPS (0.42) | FDPSMETAP1LMNAMMP2CA12 | |
| SCHEMBL6228821 | 0.98 | FDPS (0.44) | FDPSMETAP1LMNAMMP2CA12 | |
| SCHEMBL3794209 | 0.77 | METAP1 (0.38) | FDPSMETAP1MMP2CA12CA1 | |
| SCHEMBL4088811 | 0.77 | METAP1 (0.38) | FDPSMETAP1MMP2CA12CA1 | |
| SCHEMBL27864692 | 0.77 | LMNA (0.36) | FDPSMETAP1LMNAMMP2CA12 | |
| SCHEMBL12076033 | 0.75 | FDPS (0.37) | FDPSMETAP1LMNAMMP2CA12 | |
| SCHEMBL27466632 | 0.74 | FDPS (0.42) | FDPSLMNAGRM4 | |
| SCHEMBL27448352 | 0.74 | FDPS (0.38) | FDPSLMNAEPHX1 | |
| SCHEMBL6056331 | 0.72 | FDPS (0.41) | FDPSLMNAGRM4 | |
| SCHEMBL6352733 | 0.72 | MMP2 (0.37) | FDPSMETAP1MMP2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515709-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | Warner-Lambert Company LLC (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1480639-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004002462-A2 | USE OF AN ALPHA2DELTA LIGAND SUCH AS GABAPENTIN OR PREGABALIN FOR TREATING TTENTION DEFICIT HYPERACTIVITY DISORDER | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |